D. W. Nebert, Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin Genet, vol.56, pp.247-58, 1999.

J. De-leon, S. C. Armstrong, and K. L. Cozza, Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19, Psychosomatics. févr, vol.47, issue.1, pp.75-85, 2006.

J. Kirchheiner, K. Nickchen, M. Bauer, M. Wong, J. Licinio et al., Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response, Mol Psychiatry. mai, vol.9, issue.5, pp.442-73, 2004.

S. Eum, A. M. Lee, and J. R. Bishop, Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations, Dialogues Clin Neurosci, vol.18, issue.3, pp.323-360, 2016.

J. G. Pouget, T. A. Shams, A. K. Tiwari, and D. J. Müller, Pharmacogenetics and outcome with antipsychotic drugs, Dialogues Clin Neurosci. déc, vol.16, issue.4, pp.555-66, 2014.

M. J. Arranz and J. De-leon, Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research, Mol Psychiatry. août, vol.12, issue.8, pp.707-754, 2007.

W. E. Evans and M. V. Relling, Pharmacogenomics: translating functional genomics into rational therapeutics, Science, vol.286, issue.5439, pp.487-91, 1999.

W. E. Evans and J. A. Johnson, Pharmacogenomics: the inherited basis for interindividual differences in drug response, Annu Rev Genomics Hum Genet, vol.2, pp.9-39, 2001.

M. Ingelman-sundberg, Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity, Pharmacogenomics J, vol.5, issue.1, pp.6-13, 2005.

C. Hiemke, N. Bergemann, H. W. Clement, A. Conca, J. Deckert et al., Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update, Pharmacopsychiatry. janv, vol.51, issue.1-02, pp.9-62, 2017.
DOI : 10.1055/s-0037-1600991

URL : http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0037-1600991.pdf

D. A. Mrazek, Psychiatric pharmacogenomic testing in clinical practice, Dialogues Clin Neurosci, vol.12, issue.1, pp.69-76, 2010.

Z. Desta, X. Zhao, J. Shin, and D. A. Flockhart, Clinical significance of the cytochrome P450 2C19 genetic polymorphism, Clin Pharmacokinet, vol.41, issue.12, pp.913-58, 2002.

J. K. Hicks, K. Sangkuhl, J. J. Swen, V. L. Ellingrod, D. J. Müller et al., Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update, Clin Pharmacol Ther. 20 déc, 2016.

A. Llerena, P. Dorado, E. M. Peñas-lledó, and M. C. Cáceres, De la Rubia A. Low frequency of CYP2D6 poor metabolizers among schizophrenia patients, Pharmacogenomics J. déc, vol.7, issue.6, pp.408-418, 2007.

J. Brockmöller, J. Kirchheiner, J. Schmider, S. Walter, C. Sachse et al., The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment, Clin Pharmacol Ther, vol.72, issue.4, pp.438-52, 2002.

A. A. Dahl, A. Løwert, S. Asserson, L. Bjarking, J. Berglund et al., Hydroxylation polymorphism of debrisoquine hydroxylase (CYP2D6) in patients with schizophrenia in Norway and Denmark, Hum Psychopharmacol Clin Exp, vol.13, issue.7, pp.509-520, 1998.

A. K. Daly, J. B. Leathart, S. J. London, and J. R. Idle, An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution, Hum Genet. mars, vol.95, issue.3, pp.337-378, 1995.
DOI : 10.1007/bf00225204

J. Blaisdell, H. Mohrenweiser, J. Jackson, S. Ferguson, S. Coulter et al., Identification and functional characterization of new potentially defective alleles of human CYP2C19, Pharmacogenetics. déc, vol.12, issue.9, pp.703-714, 2002.

H. Fukushima-uesaka, Y. Saito, K. Maekawa, S. Ozawa, R. Hasegawa et al., Genetic variations and haplotypes of CYP2C19 in a Japanese population, Drug Metab Pharmacokinet. août, vol.20, issue.4, pp.300-307, 2005.

J. D. Robarge, L. Li, Z. Desta, A. Nguyen, and D. A. Flockhart, The star-allele nomenclature: retooling for translational genomics, Clin Pharmacol Ther. sept, vol.82, issue.3, pp.244-252, 2007.
DOI : 10.1038/sj.clpt.6100284

J. K. Hicks, J. R. Bishop, K. Sangkuhl, D. J. Müller, Y. Ji et al., Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors, Clin Pharmacol Ther. août, vol.98, issue.2, pp.127-161, 2015.

A. Gaedigk, S. D. Simon, R. E. Pearce, L. D. Bradford, M. J. Kennedy et al., The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype

, Clin Pharmacol Ther. févr, vol.83, issue.2, pp.234-276, 2008.

A. Gaedigk, J. C. Dinh, H. Jeong, B. Prasad, and J. S. Leeder, Ten Years' Experience with the CYP2D6 Activity Score: A Perspective on Future Investigations to Improve Clinical Predictions for Precision Therapeutics, J Pers Med. 17 avr, vol.8, issue.2, 2018.

A. Haduch and W. A. Daniel, The engagement of brain cytochrome P450 in the metabolism of endogenous neuroactive substrates: a possible role in mental disorders, Drug Metab Rev. 2 déc, pp.1-41, 2018.

A. Llerena, G. Edman, J. Cobaleda, J. Benítez, D. Schalling et al., Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6, Acta Psychiatr Scand. janv, vol.87, issue.1, pp.23-31, 1993.
DOI : 10.1111/j.1600-0447.1993.tb03325.x

A. Llerena, J. Cobaleda, C. Martínez, and J. Benítez, Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype

, Eur J Drug Metab Pharmacokinet. juin, vol.21, issue.2, pp.129-167, 1996.

T. Hiroi, S. Imaoka, and Y. Funae, Dopamine formation from tyramine by CYP2D6, Biochem Biophys Res Commun. 28 août, vol.249, issue.3, pp.838-881, 1998.
DOI : 10.1006/bbrc.1998.9232

A. Yu, J. R. Idle, L. G. Byrd, K. W. Krausz, A. Küpfer et al., Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6

, Pharmacogenetics. mars, vol.13, issue.3, pp.173-81, 2003.

T. Niwa, T. Hiroi, D. Tsuzuki, S. Yamamoto, S. Narimatsu et al., Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6, Brain Res Mol Brain Res, vol.129, issue.1-2, pp.117-140, 2004.

M. Pirmohamed, M. J. Wild, N. R. Kitteringham, K. O'brien, I. E. Buchan et al., Lack association between schizophrenia and the CYP2D6 gene polymorphisms, Am J Med Genet. 9 avr, vol.67, issue.2, pp.236-243, 1996.
DOI : 10.1002/ajmg.1320670205

E. G. Jönsson, M. L. Dahl, H. K. Roh, M. Jerling, and G. C. Sedvall, Lack of association between debrisoquine 4-hydroxylase (CYP2D6) gene polymorphisms and schizophrenia

, Psychiatr Genet, vol.8, issue.1, pp.25-33, 1998.

C. H. Chen, C. C. Hung, F. C. Wei, and F. J. Koong, Debrisoquine 4-hydroxylase (CYP2D6) genetic polymorphisms and susceptibility to schizophrenia in Chinese patients from Taiwan

, Psychiatr Genet. sept, vol.11, issue.3, pp.153-158, 2001.

I. Fricke-galindo, C. Céspedes-garro, F. Rodrigues-soares, and M. Naranjo,

F. Andrés, Interethnic variation of CYP2C19 alleles, « predicted » phenotypes and « measured » metabolic phenotypes across world populations, Pharmacogenomics J. avr, vol.16, issue.2, pp.113-136, 2016.

J. K. Hicks, J. J. Swen, C. F. Thorn, K. Sangkuhl, E. D. Kharasch et al., Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants, Clin Pharmacol Ther. mai, vol.93, issue.5, pp.402-410, 2013.

I. Rudberg, B. Mohebi, M. Hermann, H. Refsum, and E. Molden, Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients, Clin Pharmacol Ther. févr, vol.83, issue.2, pp.322-329, 2008.

T. Bauer, H. J. Bouman, J. W. Van-werkum, N. F. Ford, J. M. Berg et al., Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis, BMJ. 4 août, vol.343, p.4588, 2011.

M. Payan, M. R. Rouini, N. Tajik, M. H. Ghahremani, and R. Tahvilian, Hydroxylation index of omeprazole in relation to CYP2C19 polymorphism and sex in a healthy Iranian population, Daru J Fac Pharm Tehran Univ Med Sci. 11 déc, vol.22, p.81, 2014.

A. K. Daly, Pharmacogenetics of drug metabolizing enzymes in the United Kingdom population: review of current knowledge and comparison with selected European populations. Drug Metab Pers Ther, sept, vol.30, issue.3, pp.165-74, 2015.

A. F. Favela-mendoza, G. Martinez-cortes, M. Hernandez-zaragoza, J. Salazar-flores, J. F. Muñoz-valle et al., Genetic variability of CYP2C19 in a Mexican population: contribution to the knowledge of the inheritance pattern of CYP2C19*17 to develop the ultrarapid metabolizer phenotype, J Genet. mars, vol.94, issue.1, pp.3-7, 2015.

D. Sibbing, D. Gebhard, W. Koch, S. Braun, J. Stegherr et al., Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy, J Thromb Haemost JTH. août, vol.8, issue.8, pp.1685-93, 2010.

S. C. Sim, C. Risinger, M. Dahl, E. Aklillu, M. Christensen et al., A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants, Clin Pharmacol Ther. janv, vol.79, issue.1, pp.103-116, 2006.

D. B. Stephens and J. De-leon, CYP2D6 ultra-rapid metabolizer phenotype not associated with attempted suicide in a large sample of psychiatric inpatients, Pharmacogenomics, vol.17, issue.12, pp.1295-304, 2016.

A. L. Zackrisson, B. Lindblom, and J. Ahlner, High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases, Clin Pharmacol Ther. sept, vol.88, issue.3, pp.354-363, 2010.

E. M. Peñas-lledó, H. Blasco-fontecilla, P. Dorado, C. Vaquero-lorenzo, E. Baca-garcía et al., CYP2D6 and the severity of suicide attempts, Pharmacogenomics. janv, vol.13, issue.2, pp.179-84, 2012.

S. C. Sim, L. Nordin, T. Andersson, S. Virding, M. Olsson et al., Association between CYP2C19 polymorphism and depressive symptoms, Am J Med Genet Part B Neuropsychiatr Genet Off Publ Int Soc Psychiatr Genet. sept, vol.153, issue.6, pp.1160-1166, 2010.
DOI : 10.1002/ajmg.b.31081

A. Persson, S. C. Sim, S. Virding, N. Onishchenko, and G. Schulte, Ingelman-Sundberg M. Decreased hippocampal volume and increased anxiety in a transgenic mouse model expressing the human CYP2C19 gene, Mol Psychiatry. juin, vol.19, issue.6, pp.733-774, 2014.

J. De-leon, M. T. Susce, and E. Murray-carmichael, The AmpliChip CYP450 genotyping test: Integrating a new clinical tool, Mol Diagn Ther, vol.10, issue.3, pp.135-51, 2006.